Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MGMT | P16455 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18750482 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL21090258 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL30180781 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL21090765 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25345611 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25495530 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25495560 | 0.98 | CRBN (0.30) | CRBN | |
| SCHEMBL25976305 | 0.96 | CRBN (0.31) | CRBN | |
| SCHEMBL25496794 | 0.95 | TTR (0.33) | CRBN | |
| SCHEMBL24894500 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025202223-A1 | MULTIFUNCTIONAL SYSTEM | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-10-02 | — | — | WO | disclosed |
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025076427-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024155748-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023288015-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115315263-A | Cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, SELPLG | CRBN 1414/4885MGMT 2077/4885ABCG2 159/4885 |
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | M6PR, IGF2R, ASGR1 | CRBN 2602/4885MGMT 2546/4885ABCG2 1318/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | CRBN 3454/4885MGMT 2296/4885ABCG2 675/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | CRBN 825/4885MGMT 3423/4885ABCG2 3959/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | CRBN 1066/4885MGMT 1838/4885ABCG2 1889/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CRBN 642/4885MGMT 3238/4885ABCG2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.